Xilio Development Inc Cash Flow Conversion Efficiency
Xilio Development Inc cash flow conversion efficiency. Based on the latest financial reports, Xilio Development Inc (XLO) has a cash flow conversion efficiency ratio of -0.260x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.76 Million) by net assets ($72.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Xilio Development Inc (2019–2025)
Cash flow conversion efficiency of Xilio Development Inc from 2019 to 2025. This chart illustrates how Xilio Development Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XLO stock price and chart for real-time trading data and today's change.
Xilio Development Inc Cash Flow Conversion Ratio Explained
Xilio Development Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xilio Development Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xilio Development Inc ranked by their cash flow conversion efficiency. Also see XLO market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Me2on Co. Ltd
KQ:201490
|
0.010x |
|
S.Y.PANEL Co Ltd
KQ:109610
|
-0.179x |
|
Making Science Group S.A.
MC:MAKS
|
0.767x |
|
Katmerciler Arac Ustu Ekipman Sanayi ve Ticaret AS
IS:KATMR
|
-0.038x |
|
Whitbread PLC
LSE:WTB
|
0.105x |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
0.013x |
|
Ginar Technology Co Ltd
TWO:6151
|
0.074x |
|
News Network Corporation Public Company Limited
BK:NEWS
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Xilio Development Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Xilio Development Inc from 2019 to 2025. Review Xilio Development Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.27 Million | $-4.99 Million | -0.142x | +86.45% |
| 2024-12-31 | $17.60 Million | $-18.38 Million | -1.044x | +43.95% |
| 2023-12-31 | $36.83 Million | $-68.62 Million | -1.863x | -159.96% |
| 2022-12-31 | $105.65 Million | $-75.72 Million | -0.717x | -64.59% |
| 2021-12-31 | $185.43 Million | $-80.75 Million | -0.435x | -106.38% |
| 2020-12-31 | $-5.29 Million | $-36.09 Million | 6.829x | +1573.87% |
| 2019-12-31 | $38.51 Million | $-17.84 Million | -0.463x | -- |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumo… Read more